Escherichia coli Infections - Pipeline Review, H1 2017

  • ID: 4267380
  • Report
  • 152 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abgentis Ltd
  • Cellceutix Corp
  • GangaGen Inc
  • Johnson & Johnson
  • Nabriva Therapeutics AG
  • Pherecydes Pharma SA
  • MORE
Escherichia coli Infections - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Escherichia coli Infections - Pipeline Review, H1 2017, provides an overview of the Escherichia coli Infections (Infectious Disease) pipeline landscape.

Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. Escherichia coli infections are caused by coming into contact with the feces, or stool, of humans or animals or drink water or eat food that has been contaminated by feces. Symptoms include diarrhea, which may range from mild and watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and vomiting. The predisposing factors include age, weakened immune systems and eating certain types of food like undercooked hamburger, unpasteurized milk, apple juice or cider and soft cheeses made from raw milk. Treatment includes antibiotics and healthy life style.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Escherichia coli Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Escherichia coli Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 30 and 13 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 15 molecules, respectively.

Escherichia coli Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Escherichia coli Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Escherichia coli Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Escherichia coli Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Escherichia coli Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Escherichia coli Infections (Infectious Disease)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Escherichia coli Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Escherichia coli Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abgentis Ltd
  • Cellceutix Corp
  • GangaGen Inc
  • Johnson & Johnson
  • Nabriva Therapeutics AG
  • Pherecydes Pharma SA
  • MORE
Introduction

Escherichia coli Infections - Overview

Escherichia coli Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Escherichia coli Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Escherichia coli Infections - Companies Involved in Therapeutics Development

Abgentis Ltd

Adenium Biotech ApS

AstraZeneca Plc

Atterx Biotherapeutics Inc

AvidBiotics Corp

Cellceutix Corp

ContraFect Corp

Debiopharm International SA

Emergent BioSolutions Inc

F. Hoffmann-La Roche Ltd

GangaGen Inc

Hsiri Therapeutics LLC

ImmunoClin Corp

Immuron Ltd

Johnson & Johnson

Kyorin Pharmaceutical Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Microbiotix Inc

Nabriva Therapeutics AG

Navigen Inc

Nosopharm SAS

Novabiotics Ltd

Paratek Pharmaceuticals Inc

Pherecydes Pharma SA

Phico Therapeutics Ltd

Recce Ltd

Sealife PHARMA GMBH

Soligenix Inc

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Escherichia coli Infections - Drug Profiles

A-3APO - Drug Profile

AA-139 - Drug Profile

AM-8722 - Drug Profile

ASN-200 - Drug Profile

AvR2-V10 - Drug Profile

BC-7634 - Drug Profile

BC-9074 - Drug Profile

BC-9529 - Drug Profile

BC-9563 - Drug Profile

BIZ-20131 - Drug Profile

BIZ-20132 - Drug Profile

BIZ-20133 - Drug Profile

CA-824 - Drug Profile

CC-1807 - Drug Profile

CF-301 - Drug Profile

Debio-1454 - Drug Profile

dusquetide - Drug Profile

EBX-004 - Drug Profile

Escherichia coli (whole cell) vaccine - Drug Profile

Escherichia coli vaccine - Drug Profile

Escherichia coli vaccine - Drug Profile

ETEC [strain B7A] vaccine - Drug Profile

ETEC vaccine - Drug Profile

EV-035 - Drug Profile

GN-4474 - Drug Profile

GNeg Snare - Drug Profile

GYR-12 - Drug Profile

HT-07 - Drug Profile

infectious disease vaccine - Drug Profile

interleukin-22 - Drug Profile

JNJ-63871860 - Drug Profile

JSM-11 - Drug Profile

MBX-2319 - Drug Profile

MDN-0057 - Drug Profile

mirandamycin - Drug Profile

NBTI-5463 - Drug Profile

NOSO-95179 - Drug Profile

NP-432 - Drug Profile

omadacycline tosylate - Drug Profile

Onc-72 - Drug Profile

P-100031 - Drug Profile

Peptides for Infectious Diseases - Drug Profile

Polysaccharides for Bacterial Infections - Drug Profile

PP-0121 - Drug Profile

Proteins for Infectious Diseases - Drug Profile

PT-5 - Drug Profile

RECCE-327 - Drug Profile

Recombinant Protein for Escherichia Coli Infections - Drug Profile

RX-05 - Drug Profile

RXP-873 - Drug Profile

SE-1 - Drug Profile

Shigetec - Drug Profile

SLP-0901 - Drug Profile

SLP-0905 - Drug Profile

Small Molecule for Malaria and Bacterial Infections - Drug Profile

Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile

Small Molecule to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile

Small Molecules for Escherichia coli Infections - Drug Profile

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile

Small Molecules to Inhibit DbpA for Escherichia coli Infections - Drug Profile

Small Molecules to Inhibit RecA for Bacterial Infections - Drug Profile

SPR-741 - Drug Profile

Synthetic Peptide for Oncology and Infectious Disease - Drug Profile

Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile

Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections - Drug Profile

Synthetic Peptides for Escherichia Coli Infections - Drug Profile

Synthetic Peptides for Infectious Disease - Drug Profile

TN-5 - Drug Profile

TP-6076 - Drug Profile

Escherichia coli Infections - Dormant Projects

Escherichia coli Infections - Discontinued Products

Escherichia coli Infections - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Escherichia coli Infections, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Companies, H1 2017 (Contd..2), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Companies, H1 2017 (Contd..2), H1

Products under Development by Universities/Institutes, H1

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Escherichia coli Infections - Pipeline by Abgentis Ltd, H1

Escherichia coli Infections - Pipeline by Adenium Biotech ApS, H1

Escherichia coli Infections - Pipeline by AstraZeneca Plc, H1

Escherichia coli Infections - Pipeline by Atterx Biotherapeutics Inc, H1

Escherichia coli Infections - Pipeline by AvidBiotics Corp, H1

Escherichia coli Infections - Pipeline by Cellceutix Corp, H1

Escherichia coli Infections - Pipeline by ContraFect Corp, H1

Escherichia coli Infections - Pipeline by Debiopharm International SA, H1

Escherichia coli Infections - Pipeline by Emergent BioSolutions Inc, H1

Escherichia coli Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1

Escherichia coli Infections - Pipeline by GangaGen Inc, H1

Escherichia coli Infections - Pipeline by Hsiri Therapeutics LLC, H1

Escherichia coli Infections - Pipeline by ImmunoClin Corp, H1

Escherichia coli Infections - Pipeline by Immuron Ltd, H1

Escherichia coli Infections - Pipeline by Johnson & Johnson, H1

Escherichia coli Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1

Escherichia coli Infections - Pipeline by Melinta Therapeutics Inc, H1

Escherichia coli Infections - Pipeline by Merck & Co Inc, H1

Escherichia coli Infections - Pipeline by Microbiotix Inc, H1

Escherichia coli Infections - Pipeline by Nabriva Therapeutics AG, H1

Escherichia coli Infections - Pipeline by Navigen Inc, H1

Escherichia coli Infections - Pipeline by Nosopharm SAS, H1

Escherichia coli Infections - Pipeline by Novabiotics Ltd, H1

Escherichia coli Infections - Pipeline by Paratek Pharmaceuticals Inc, H1

Escherichia coli Infections - Pipeline by Pherecydes Pharma SA, H1

Escherichia coli Infections - Pipeline by Phico Therapeutics Ltd, H1

Escherichia coli Infections - Pipeline by Recce Ltd, H1

Escherichia coli Infections - Pipeline by Sealife PHARMA GMBH, H1

Escherichia coli Infections - Pipeline by Soligenix Inc, H1

Escherichia coli Infections - Pipeline by Syntiron LLC, H1

Escherichia coli Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H1

Escherichia coli Infections - Dormant Projects, H1

Escherichia coli Infections - Dormant Projects, H1 2017 (Contd..1), H1

Escherichia coli Infections - Dormant Projects, H1 2017 (Contd..2), H1

Escherichia coli Infections - Discontinued Products, H1

List of Figures:

Number of Products under Development for Escherichia coli Infections, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abgentis Ltd
  • Adenium Biotech ApS
  • AstraZeneca Plc
  • Atterx Biotherapeutics Inc
  • AvidBiotics Corp
  • Cellceutix Corp
  • ContraFect Corp
  • Debiopharm International SA
  • Emergent BioSolutions Inc
  • F. Hoffmann-La Roche Ltd
  • GangaGen Inc
  • Hsiri Therapeutics LLC
  • ImmunoClin Corp
  • Immuron Ltd
  • Johnson & Johnson
  • Kyorin Pharmaceutical Co Ltd
  • Melinta Therapeutics Inc
  • Merck & Co Inc
  • Microbiotix Inc
  • Nabriva Therapeutics AG
  • Navigen Inc
  • Nosopharm SAS
  • Novabiotics Ltd
  • Paratek Pharmaceuticals Inc
  • Pherecydes Pharma SA
  • Phico Therapeutics Ltd
  • Recce Ltd
  • Sealife PHARMA GMBH
  • Soligenix Inc
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll